Search research articles
Contact Us
Filters
Showing results (481-490 of 740) with videos related to
Page
of 74
Sort By:
British Journal of Cancer
|
June 4, 2020
Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial
Angelos Koutras, Flora Zagouri, Georgia-Angeliki Koliou, et al.
Blood
|
September 12, 2015
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study
Efstathios Kastritis, Maria Gavriatopoulou, Marie-Christine Kyrtsonis, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 15, 2026
Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function
Xi Chen, Shawn Hakim, Yi Ting Kayla Lien, et al.
Blood Advances
|
November 17, 2021
Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies
Tina Bagratuni, Athina Markou, Dimitrios Patseas, et al.
Leukemia
|
May 24, 2020
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
Meletios A Dimopoulos, Xavier Leleu, Philippe Moreau, et al.
Haematologica
|
February 15, 2024
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study
Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, et al.
Blood Cancer Journal
|
January 11, 2023
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma
Wee-Joo Chng, Sagar Lonial, Gareth J Morgan, et al.
Blood Cancer Journal
|
August 3, 2021
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, et al.
Hemasphere
|
February 8, 2021
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
Meletios A Dimopoulos, Philippe Moreau, Evangelos Terpos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 23, 2025
Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis
Despina Fotiou, Foteini Theodorakakou, Eirini Solia, et al.
Page
of 74
Search research articles
Search
Showing results (481-490 of 740) with videos related to
Sort By:
Page
of 74
British Journal of Cancer
|
June 4, 2020
Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial
Angelos Koutras, Flora Zagouri, Georgia-Angeliki Koliou, et al.
Blood
|
September 12, 2015
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study
Efstathios Kastritis, Maria Gavriatopoulou, Marie-Christine Kyrtsonis, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 15, 2026
Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function
Xi Chen, Shawn Hakim, Yi Ting Kayla Lien, et al.
Blood Advances
|
November 17, 2021
Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies
Tina Bagratuni, Athina Markou, Dimitrios Patseas, et al.
Leukemia
|
May 24, 2020
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
Meletios A Dimopoulos, Xavier Leleu, Philippe Moreau, et al.
Haematologica
|
February 15, 2024
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study
Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, et al.
Blood Cancer Journal
|
January 11, 2023
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma
Wee-Joo Chng, Sagar Lonial, Gareth J Morgan, et al.
Blood Cancer Journal
|
August 3, 2021
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, et al.
Hemasphere
|
February 8, 2021
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
Meletios A Dimopoulos, Philippe Moreau, Evangelos Terpos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 23, 2025
Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis
Despina Fotiou, Foteini Theodorakakou, Eirini Solia, et al.
Page
of 74